| Date Filed | Type | Description |
| 10/03/2023 |
4
| Boudes Pol F (Director) has filed a Form 4 on Protalix BioTherapeutics, Inc.|
Txns:
| Granted 61,676 options to buy
@ $1.66, valued at
$102.4k
|
|
| 10/03/2023 |
4
| Melincoff Gwen A (Director) has filed a Form 4 on Protalix BioTherapeutics, Inc.|
Txns:
| Granted 61,676 options to buy
@ $1.66, valued at
$102.4k
|
|
| 10/03/2023 |
4
| Bar-Shalev Amos (Director) has filed a Form 4 on Protalix BioTherapeutics, Inc.|
Txns:
| Granted 61,676 options to buy
@ $1.66, valued at
$102.4k
|
|
| 10/03/2023 |
4
| Ben Zvi Shmuel (Director) has filed a Form 4 on Protalix BioTherapeutics, Inc.|
Txns:
| Granted 61,676 options to buy
@ $1.66, valued at
$102.4k
|
|
| 10/03/2023 |
4
| Schwartz Aharon (Director) has filed a Form 4 on Protalix BioTherapeutics, Inc.|
Txns:
| Granted 61,676 options to buy
@ $1.66, valued at
$102.4k
|
|
| 08/17/2023 |
4
| Bashan Dror (President and CEO) has filed a Form 4 on Protalix BioTherapeutics, Inc.|
Txns:
| Granted 800,000 shares
@ $0 |
|
| 08/17/2023 |
4
| Rubin Eyal (Sr. VP and CFO) has filed a Form 4 on Protalix BioTherapeutics, Inc.|
Txns:
| Granted 201,903 shares
@ $0 |
|
| 08/17/2023 |
4
| Hayon Yael (VP, Research & Development) has filed a Form 4 on Protalix BioTherapeutics, Inc.|
Txns:
| Granted 35,115 shares
@ $0
Granted 35,115 options to buy
@ $1.99, valued at
$69.9k
|
|
| 08/17/2023 |
4
| Naos Yaron (Sr. VP, Operations) has filed a Form 4 on Protalix BioTherapeutics, Inc.|
Txns:
| Granted 187,344 shares
@ $0 |
|
| 01/05/2023 |
4
| Schwartz Aharon (Director) has filed a Form 4 on Protalix BioTherapeutics, Inc.|
Txns:
| Bought 110,000 shares
@ $1.4165, valued at
$155.8k
|
|
| 09/09/2022 |
4
| Ben Zvi Shmuel (Director) has filed a Form 4 on Protalix BioTherapeutics, Inc.|
Txns:
| Granted 10,000 options to buy
@ $1.03, valued at
$10.3k
|
|
| 09/09/2022 |
4
| Naos Yaron (Sr. VP, Operations) has filed a Form 4 on Protalix BioTherapeutics, Inc.|
Txns:
| Granted 340,000 options to buy
@ $1.03, valued at
$350.2k
|
|
| 09/09/2022 |
4
| Hayon Yael (VP, Research & Development) has filed a Form 4 on Protalix BioTherapeutics, Inc.|
Txns:
| Granted 250,000 options to buy
@ $1.03, valued at
$257.5k
|
|
| 09/09/2022 |
4
| Rubin Eyal (Sr. VP and CFO) has filed a Form 4 on Protalix BioTherapeutics, Inc.|
Txns:
| Granted 350,000 options to buy
@ $1.03, valued at
$360.5k
|
|
| 09/09/2022 |
4
| Bashan Dror (President and CEO) has filed a Form 4 on Protalix BioTherapeutics, Inc.|
Txns:
| Granted 750,000 options to buy
@ $1.03, valued at
$772.5k
|
|
| 09/09/2022 |
4
| Schwartz Aharon (Director) has filed a Form 4 on Protalix BioTherapeutics, Inc.|
Txns:
| Granted 50,000 options to buy
@ $1.03, valued at
$51.5k
|
|
| 09/09/2022 |
4
| Bronfeld Zeev (Director) has filed a Form 4 on Protalix BioTherapeutics, Inc.|
Txns:
| Granted 100,000 options to buy
@ $1.03, valued at
$103k
|
|
| 09/09/2022 |
4
| Bar-Shalev Amos (Director) has filed a Form 4 on Protalix BioTherapeutics, Inc.|
Txns:
| Granted 50,000 options to buy
@ $1.03, valued at
$51.5k
|
|
| 09/09/2022 |
4
| Melincoff Gwen A (Director) has filed a Form 4 on Protalix BioTherapeutics, Inc.|
Txns:
| Granted 50,000 options to buy
@ $1.03, valued at
$51.5k
|
|
| 09/09/2022 |
4
| Boudes Pol F (Director) has filed a Form 4 on Protalix BioTherapeutics, Inc.|
Txns:
| Granted 50,000 options to buy
@ $1.03, valued at
$51.5k
|
|
| 07/05/2022 |
4
| Ben Zvi Shmuel (Director) has filed a Form 4 on Protalix BioTherapeutics, Inc.|
Txns:
| Granted 40,000 options to buy
@ $1.09, valued at
$43.6k
|
|
| 07/05/2022 |
3
| Ben Zvi Shmuel (Director) has filed a Form 3 on Protalix BioTherapeutics, Inc. |
| 04/13/2022 |
4
| Bashan Dror (President and CEO) has filed a Form 4 on Protalix BioTherapeutics, Inc.|
Txns:
| Bought 68,000 shares
@ $1.5, valued at
$102k
|
|
| 02/28/2022 |
4
| Rubin Eyal (Sr. VP and CFO) has filed a Form 4 on Protalix BioTherapeutics, Inc.|
Txns:
| Granted 121,951 shares
@ $0 |
|
| 02/28/2022 |
4
| Bashan Dror (President and CEO) has filed a Form 4 on Protalix BioTherapeutics, Inc.|
Txns:
| Granted 637,531 shares
@ $0 |
|
| 06/03/2021 |
4
| Dexcel Pharma Technologies Ltd. (10% Owner) has filed a Form 4 on Protalix BioTherapeutics, Inc.|
Txns:
| Sold 61,211 shares
@ $2.5576, valued at
$156.6k
Sold 857,506 shares
@ $2.2534, valued at
$1.9M
|
|
| 02/16/2021 |
3
| Dexcel Pharma Technologies Ltd. (10% Owner) has filed a Form 3 on Protalix BioTherapeutics, Inc. |
| 08/14/2020 |
4/A
| Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] |
| 08/14/2020 |
4/A
| Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] |
| 08/13/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 08/13/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 08/13/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/08/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/08/2020 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
|